NDA 018960 · Hospira
Cupric Chloride In Plastic Container
Cupric Chloride · Injection
Priority reviewLast checked: Nov 20, 2026Latest source record: Jul 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Jun 26, 1986
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
748
502 serious, 42 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 18, 2026.
INDICATIONS AND USAGE Copper (Cupric Chloride Injection) is indicated for use as a supplement to intravenous solutions given for TPN. Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 26, 1986 Original approval · Type 5 - New Formulation or New Manufacturer · priority review
1 products under this application
- CUPRIC CHLORIDE IN PLASTIC CONTAINER · CUPRIC CHLORIDE EQ 0.4MG COPPER/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Cupric Chloride" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue75
- off label use74
- headache64
- nausea64
- pain61
- diarrhoea60
- drug ineffective53
- weight decreased49
- malaise43
- abdominal pain40
- anaemia37
- dizziness36
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 6 |
| 2010 | 9 |
| 2011 | 14 |
| 2012 | 13 |
| 2013 | 21 |
| 2014 | 21 |
| 2015 | 32 |
| 2016 | 60 |
| 2017 | 23 |
| 2018 | 46 |
| 2019 | 57 |
| 2020 | 52 |
| 2021 | 65 |
| 2022 | 70 |
| 2023 | 66 |
| 2024 | 64 |
| 2025 | 69 |
| 2026 | 47 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- [Crystallization test in patients with head and neck neoplasms].
Kuczkowski J, Zaorski P, Betlejewski A · Otolaryngol Pol 1995 · Clinical Trial, Controlled Clinical Trial
- Antioxidants, but not B-group vitamins increase the resistance of low-density lipoprotein to oxidation: a randomized, factorial design, placebo-controlled trial.
Woodside JV, Young IS, Yarnell JW, et al. · Atherosclerosis 1999 · Clinical Trial, Comparative Study
- Low-density lipoprotein (LDL) behavior after in vitro oxidation in three groups of diabetics.
Seghrouchni I, Drai J, Bannier E, et al. · Farmaco 2001 · Clinical Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.